3SBio Inc. (1530.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Jing Lou
Listed since: Jun 11, 2015
Employees: 6,068

Market position

Day range

Current HK$17.90

HK$17.61HK$18.24

52-week range

Current HK$17.90

HK$14.81HK$36.80

Open: HK$17.83
Previous close: HK$17.83
Volume: 29.62M; 0.89× average
Average volume: 33.21M; Average daily volume
Market cap: 44.76B HKD
Beta: 0.45; Market reference 1
50-day average: HK$17.2274; +3.90% above average
200-day average: HK$22.4234; -20.17% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 43.85B CNY
P/E (TTM): 4.62×
P/B (TTM): 1.42×
P/S (TTM): 2.16×
EV / EBITDA: 3.99×
Earnings yield: 15.84%
Free cash flow yield: 17.05%
Dividend yield: 1.40%

Profitability & efficiency

Gross margin: 91.97%
Operating margin: 61.16%
Net margin: 46.37%
Return on equity: 31.16%
Return on assets: 23.39%
Return on invested capital: 26.48%

Financial health

Debt / equity: 0.02×
Current ratio: 5.13×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

17.7B CNY+94.29%

Operating income

10.54B CNY+298.14%

Net income

8.48B CNY+305.78%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	17.7B CNY	9.11B CNY	7.82B CNY	6.86B CNY	6.38B CNY
Cost of goods sold	1.35B CNY	1.28B CNY	1.17B CNY	1.19B CNY	1.11B CNY
Gross profit	16.35B CNY	7.83B CNY	6.64B CNY	5.67B CNY	5.28B CNY
Research and development	1.52B CNY	1.33B CNY	794.79M CNY	693.17M CNY	753.87M CNY
Selling, general, and administrative	4.28B CNY	3.85B CNY	3.49B CNY	2.96B CNY	2.7B CNY
Operating expenses	5.8B CNY	5.18B CNY	4.18B CNY	3.65B CNY	3.45B CNY
Interest income	295.92M CNY	147.78M CNY	153.12M CNY	149.49M CNY	74.45M CNY
Interest expense	74.41M CNY	190.85M CNY	212.3M CNY	102.75M CNY	66.53M CNY
Depreciation and amortization	507.97M CNY	315.16M CNY	334.85M CNY	369.78M CNY	329M CNY
Operating income	10.54B CNY	2.65B CNY	2.46B CNY	2.07B CNY	1.83B CNY
Net income	8.48B CNY	2.09B CNY	1.55B CNY	1.92B CNY	1.65B CNY